secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K/A
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001356576-23-000053
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q2 2023 revenues $135.5M, down 20% YoY; GAAP operating loss $17.6M
---------------------------------------------------------------------------

- Qelbree net sales $31.0M (+179%), GOCOVRI $28.8M (+17%) in Q2 2023 vs Q2 2022.
- Trokendi XR net sales fell 73% in Q2 and 60% in H1 2023 due to generic erosion.
- GAAP net loss ($0.8M) or ($0.02)/diluted share; adjusted operating earnings $10.0M vs $37.6M.
- Cash & securities $189.1M at June 30, 2023, down from $555.2M due to $402.5M note repayment.
- Full-year 2023 guidance reaffirmed: total revenue $580-$620M, GAAP operating loss $(30)-$(10)M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657623000053/0001356576-23-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657623000053/supn-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001356576-23-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer